Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice

Tingting Wei1,*, Liangcai Zhao1,*, Jianmin Jia1, Huanhuan Xia1, Yao Du1, Qiuting Lin1, Xiaodong Lin1, Xinjian Ye2, Zhihan Yan2 & Hongchang Gao1

Diabetic nephropathy (DN) is one of the lethal manifestations of diabetic systemic microvascular disease. Elucidation of characteristic metabolic alterations during diabetic progression is critical to understand its pathogenesis and identify potential biomarkers and drug targets involved in the disease. In this study, 1H nuclear magnetic resonance (1H NMR)-based metabonomics with correlative analysis was performed to study the characteristic metabolites, as well as the related pathways in urine and kidney samples of db/db diabetic mice, compared with age-matched wildtype mice. The time trajectory plot of db/db mice revealed alterations, in an age-dependent manner, in urinary metabolic profiles along with progression of renal damage and dysfunction. Age-dependent and correlated metabolite analysis identified that cis-aconitate and allantoin could serve as biomarkers for the diagnosis of DN. Further correlative analysis revealed that the enzymes dimethylarginine dimethylaminohydrolase (DDAH), guanosine triphosphate cyclohydrolase I (GTPCH I), and 3-hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA lyase) were involved in dimethylamine metabolism, ketogenesis and GTP metabolism pathways, respectively, and could be potential therapeutic targets for DN. Our results highlight that metabonomic analysis can be used as a tool to identify potential biomarkers and novel therapeutic targets to gain a better understanding of the mechanisms underlying the initiation and progression of diseases.

Diabetic nephropathy (DN), a leading cause of end stage renal disease, is considered a common microvascular complication of diabetic mellitus, with a high risk of atherosclerotic disease and premature death1. Previous studies have shown that the pathogenesis of DN is complex and involves multiple factors, including the activation of the sorbitol aldose reductase, increased production of advanced glycation end products, increased activity of protein kinase C, and altered expression of cyclin-dependent kinases2. Although several factors are proposed to be involved in the progression of the disease, the systemic and characteristic metabolic alterations involved in the development of DN remain unclear.

Metabonomic analysis is a systems biology approach that provides global metabolic information in biological samples3,4. This approach has been widely used in the diagnosis and treatment of diabetes5,6. Our previous studies using metabonomic approach have identified characteristic differences in the metabolite composition of the urine, kidney, and serum samples of STZ-induced type 1 diabetic rats collected at different time points7,8. Further, analysis of the temporal evolution of key metabolites revealed changes in energy metabolism and methylamine metabolism during the onset and progression of diabetes9. Li et al. reported that perturbations in the TCA cycle metabolites play a significant role in the pathogenesis of...
by biochemical analysis are shown in Table 1. Compared with the and renal damage with age 12. With the goals of discovering specific biomarkers of disease progression, we used the 

metabolic changes associated with the development of type 2 diabetic mellitus are not well understood. To comprehensively profile the changes in metabolite levels associated with the progression of DN, we studied the metabolic alterations in the urine and renal tissue samples obtained from the 

db/db mice. 

To explore the characteristic alterations in urinary metabolites during the progression of DN, we used the 

of DN in db/db mice10. Further, Liu et al. observed changes in several metabolites along with defective pathways in the serum and urine samples of a nonhuman primate model of DN11. However, the global metabolic changes associated with the development of type 2 diabetic mellitus are not well understood.

Table 1. Morphometric and metabolic parameters. Values are expressed as mean ± SE; Keys: CRE, urine creatinine; UACR, urinary albumin to creatinine ratio; *P < 0.05, **P < 0.01 compared with age-matched wildtype mice.

|                     | 9-wk       | 11-wk      | 13-wk      | 15-wk      | 17-wk      |
|---------------------|------------|------------|------------|------------|------------|
| Body weight, g      |            |            |            |            |            |
| wildtype mice       | 22.59 ± 0.35 | 19.91 ± 0.28 | 20.35 ± 0.31 | 20.88 ± 0.32 | 22.21 ± 0.34 |
| db/db mice          | 41.14 ± 0.96" | 40.34 ± 1.09" | 42.35 ± 1.14" | 45.36 ± 1.24" | 50.85 ± 0.96" |
| Serum glucose, mmol/L |            |            |            |            |            |
| wildtype mice       | 6.31 ± 0.35 | 4.92 ± 0.33 | 5.20 ± 0.34 | 6.56 ± 0.89 | 4.93 ± 0.11 |
| db/db mice          | 17.08 ± 0.88" | 20.72 ± 2.15" | 17.33 ± 1.00" | 12.94 ± 0.83" | 10.49 ± 0.35" |
| CRE, mg/dL          |            |            |            |            |            |
| wildtype mice       | 10.52 ± 0.48 | 14.51 ± 1.57 | 14.35 ± 1.81 | 16.95 ± 1.89 | 19.14 ± 2.33 |
| db/db mice          | 6.02 ± 0.81" | 4.68 ± 0.55" | 4.50 ± 0.53" | 3.80 ± 0.64" | 3.48 ± 0.71" |
| UACR, mg/mmol       |            |            |            |            |            |
| wildtype mice       | 56.57 ± 9.2 | 83.77 ± 12.15 | 77.82 ± 10.86 | 65.76 ± 5.93 | 65.13 ± 8.95 |
| db/db mice          | 95.47 ± 6.50" | 135.00 ± 18.57" | 131.37 ± 18.57" | 138.28 ± 19.68" | 153.62 ± 27.06" |

Results
Clinical biochemistry and histopathology. Morphometric and body fluid parameters determined by biochemical analysis are shown in Table 1. Compared with the wildtype mice, the db/db mice exhibited hyperglycemia and increase in body weight throughout the experimental period (from 9 weeks to 17 weeks). Urinalysis revealed significantly elevated urinary albumin to creatinine ratio (UACR) and reduced urine creatinine (CRE) in db/db mice, indicating renal dysfunction. As reported previously, the UACR levels increased with age in db/db mice, suggesting the progression of the DN10.

Figure 1 shows representative images of the histological examination of hematoxylin-eosin (HE)-stained and periodic acid-schiff (PAS)-stained sections of kidneys from 17-week-old wildtype and db/db mice. HE staining results revealed prominent glomerular lesions in renal parenchyma at the late stage of DN in db/db mice. PAS-stained sections showed clear evidence of glomerulosclerosis. Diffuse mesangial matrix expansion and thickening of the glomerular capillary basement membranes observed in the kidney tissues of 17-week-old db/db mice are consistent with previous reports on chronic renal injury in diabetic animals12. These results indicated that at the age of 17 weeks the db/db mice develop clear manifestations of renal tissue damage and dysfunction.

NMR spectra and pattern recognition analysis of urine samples. Figure 2 illustrates typical 600 MHz 1H NMR spectra of urine samples obtained from the wildtype and the db/db mice. The spectral resonances of the metabolites were assigned based on our previous study9 and the 600 MHz library of the Chenomx NMR suite 7.0 (Chenomx Inc., Edmonton, Canada). The spectroscopic profiling of the two groups revealed obvious alterations in metabolite concentrations. As expected, compared with wildtype mice, the db/db mice showed much stronger signal intensity for glucose, indicating glycosuria, a common feature of DN.

To explore the characteristic alterations in urinary metabolites during the progression of DN, urine samples collected at specific intervals from the db/db mice and their age-matched wildtype controls were analyzed by NMR-based metabonomics. The projection to latent structure discriminant analysis (PLS-DA) mean trajectory showed a characteristic difference in metabolic pattern between the two groups (Fig. 3A). Additionally, results from the db/db mice revealed obvious trajectory space from 9 weeks to 17 weeks, while the wildtype mice occupied a minor position in the plot, suggesting that the observed changes in metabolic profiles were related to the progression of the disease, but not due to the age of mice. To identify the DN-specific metabolic changes, urinary metabolic trajectory from the db/ db mice was analyzed (Fig. 3B). As indicated by the arrow, the urine samples of 9-week-old db/db mice were distinguishable from that of the 11-week-old mice and the other three samples. The age-dependent
metabolic profiles indicated continuous metabolic modifications throughout the experimental period in \textit{db/db} mice, which were manifestations of the pathological insult. Figure 3C illustrates the corresponding loading plot with color-coded correlation coefficients (|r|) of metabolites. The plot showed differences in the levels of metabolites, including 3-HB, acetate, acetone, acetocacetate, succinate, citrate, methylamine, creatine, TMAO, glycine, creatinine, hippurate, allantoin, cis-aconitate, fumarate, and 3-indoxylsulfate.

Figure 1. Histological examination of kidney tissues. Representative HE and PAS stains of kidney tissues from 17-week-old \textit{wildtype} mice and \textit{db/db} mice.

Figure 2. NMR spectra of urine samples. Representative $^1$H NMR spectra of urine samples obtained from the \textit{wildtype} mice (A) and \textit{db/db} mice (B), respectively.
Temporal changes in urinary metabolite levels and screening for potential biomarkers. The trajectory plots of urinary metabolic profiles matched with different periods of db/db mice, including early stage (9 weeks), middle stage (13 weeks), and late stage (17 weeks) of DN, as defined previously. This difference in metabolite profiles in different age groups of the db/db mice can be attributed to the metabolic changes associated with disease progression.

The changes in key metabolites from the onset to the progression of the disease are shown in Fig. 4. Compared with the wildtype mice, elevated levels of several TCA-cycle intermediates (2-oxoglutarate, citrate, cis-aconitate, and fumarate) were evident in the samples from db/db mice. At 9 weeks, there were no obvious changes in citrate and cis-aconitate levels between the wildtype and db/db mice. However, their levels were higher during the middle and late stages of DN (Fig. 4A). 2-oxoglutarate and fumarate levels were high at the early stage of DN and were partly restored to control levels during the late stages. Pyruvate, which is produced by glucose metabolism, was reduced during the progression of DN, with a drastic reduction seen at 17 weeks in db/db mice. Additionally, lactate levels were increased in db/db animals of 9 weeks (Fig. 4B). These changes indicated altered glucose metabolism during the development and progression of DN. Compared with the wildtype mice, creatinine levels, which reflect renal function, were lower in the db/db mice throughout the experimental period. Allantoin, 1-methylnicotinamide (MNA), and hippurate were altered in an age-dependent manner. For example, at the age of 13 weeks, hippurate levels were elevated and reached a maximum at 17 weeks in the db/db mice, suggesting a strong correlation between hippurate concentration and progression of the disease (Fig. 4C). The lipid byproducts, acetate, 3-hydroxybutyrate (3-HB), and acetoacetate, were reduced in the db/db mice throughout the experimental period, suggesting reduced lipid metabolism in DN (Fig. 4D).
Pattern recognition and quantitative analysis of renal metabolites. Representative $^1$H-NMR spectra and peak assignments of the metabolites of the kidney tissue extracts obtained from 17-week-old $\text{db/db}$ mice are shown in Fig. 5. Similar to that of the urinary metabolites, the PLS-DA score plot of the renal tissue samples (Fig. 6A) from the 17-week-old $\text{db/db}$ mice and wildtype mice showed clear differences along the PC1 direction. The validation plot of permutation tests showed that the PLS-DA model built for $\text{db/db}$ mice and wildtype mice was robust and credible (Fig. 6B). The corresponding loading plot (Fig. 6C) indicated that the variables corresponding to 3-HB, lactate, acetate, glutamate, succinate, creatinine, choline, glycerophosphocholine (GPC), trimethylamine oxide (TMAO), myo-inositol, glycine, uridine, inosine, fumarate, phenylalanine, and niacinamide were responsible for the separation.

Table 2 shows the relative integrals of metabolites in kidney extracts of the $\text{db/db}$ and wildtype mice. In addition to the urine samples with holistic metabolic characteristics, the metabolic alterations in the kidney tissue shed light on the pathogenic factors involved in DN. Similar to the urinary metabolites, there was higher levels of lactate, and lower levels of acetate, 3-HB, and creatinine in the kidney of $\text{db/db}$ mice than that of the wildtype mice. In addition, reduced levels of glutamate, glycine, tyrosine, uracil, uridine, guanosine triphosphate (GTP), and choline, and significantly increased levels of myo-inositol and TMAO were observed in $\text{db/db}$ mice.

Correlation analysis of urinary and renal metabolites. To investigate the relationship among the metabolites, their levels in the urine and kidney samples from 17-week-old wildtype and $\text{db/db}$ mice were correlated separately using the Pearson's correlation (Fig. 7). UACR is a well-known marker of kidney damage and dysfunction. Analysis of the correlation between UACR and identified metabolites can be used to screen for specific biomarkers. Remarkably, the UACR showed a negative correlation with cis-aconitate, dimethylamine (DMA), 3-HB, acetoacetate, creatinine, allantoin, and a positive correlation with fumarate in the urine samples of $\text{db/db}$ mice. In addition, lactate levels were positively correlated with UACR in the urine samples of $\text{db/db}$ mice, whereas a negative correlation was observed in the wildtype mice (Fig. 7A,B). In the kidney tissue samples of $\text{db/db}$ mice, UACR was positively correlated...
with phenylalanine, fumarate, acetate, glutamate, glycine, uridine, and GTP, and negatively correlated with lactate. No such correlation was evident in the wildtype mice (Fig. 7C,D). These metabolites, which showed significant correlation with UACR in the db/db mice, could serve as potential biomarkers for assessing the progression of DN.

A correlation analysis of the urinary and kidney tissue metabolites from 17-week-old mice was performed to gain insights into the pathogenic characteristics and pathways involved in DN. Positive correlation indicated the relationship of the metabolites with certain pathways, whereas a negative correlation suggested the metabolites may be of different pathways. For example, in the urinary metabolites of db/db mice, positive correlations of cis-aconitate with citrate and fumarate, DMA with allantoin and 3-indoxylsulfate, 3-HB and acetoacetate with cis-aconitate, creatinine and 3-indoxylsulfate, and hippurate with methylamine and acetone were evident. Further, hippurate from the urine samples of db/db mice was negatively correlated with succinate, and acetate (Fig. 7A,B). No such correlations were observed in the urinary metabolites of wildtype mice.

Significant correlations were also observed among the metabolites from the kidney tissue samples of db/db mice (Fig. 7C,D). Phenylalanine positively correlated with tyrosine. Lactate negatively correlated with creatine, TMAO, myo-inositol, glutamate and glycine. Glutamate and glycine were positively correlated with fumarate, acetate, and GTP, and negatively correlated with lactate. The correlations among the metabolites in db/db mice suggested DN-specific alterations in specific metabolic pathways.

Disturbed metabolic pathways in db/db mice. The pathway analysis, including the analysis of TCA cycle, glycolysis, methylamine metabolism, purine metabolism, pyrimidine metabolism, and fatty acid β-oxidation, was performed using the KEGG database (http://www.genome.jp/kegg/pathway.html). Results showing alterations in metabolic pathways during the progression of DN are summarized in Fig. 8. The reduced concentrations of methylamine, DMA, TMA, and choline in the db/db mice suggested the down-regulation of the methylamine pathway. The lower levels of 3-HB, acetone, acetoacetate, and acetate indicated reduced or slow fatty acid β-oxidation in the db/db mice. These metabolic changes and the associated pathways provide insights into the mechanisms involved in the development and progression of DN.

Discussion

DN is a serious complication that develops in a significant proportion of patients with diabetes. Although various factors have been found to influence the onset and progression of DN, the global metabolic alterations associated with renal injury remained poorly characterized. In this study, we used 1H-NMR and correlative analysis to identify the characteristic metabolic alterations and pathways associated with the development and progression of DN in the urine and renal tissue samples of db/db mice. The key enzymes and proteins involved in the pathways identified as playing a role in the development and progression of the disease could serve as potential drug targets.
Renal dysfunction and damages in the db/db mice. The reduced creatinine levels and elevated UACR values observed in the urine samples of 9- to 13-week-old db/db mice confirmed impaired renal function. Creatinine, an indicator of glomerular filtration rate, is formed exclusively from creatine in the body. Creatinine levels were lower in the urine samples collected at five different time-points from the db/db mice, indicating renal dysfunction, mild or severe, throughout the experimental period. Moreover, the gradual increase in UACR, a reliable and convenient measure of renal dysfunction, observed in the db/db mice indicates the progression of DN with age. These results are consistent with the changes in renal morphology revealed by histological staining with HE and PAS, which showed clear glomerulosclerosis lesions in 17-week-old db/db mice, an indication of renal dysfunction and tissue damage seen during the late stages of DN.

Candidate biomarker screening and identification. Our NMR-based metabonomic analysis revealed several metabolic changes in the urine samples of db/db mice. These changes included higher levels of 2-oxoglutarate, citrate, cis-aconitate, fumarate, lactate, hippurate, and MNA, and lower levels of pyruvate, methylamine, creatinine, allantoin, acetate, 3-HB, and acetoacetate. Additionally, analysis of the temporal changes in metabolites revealed that the metabolite levels in urine, especially those of 2-oxoglutarate, citrate, cis-aconitate, fumarate, pyruvate, allantoin, hippurate, and MNA, underwent age-dependent changes during the progression of DN. These characteristic changes could serve as potential biomarkers for the diagnosis of DN. Finally, correlation analysis of urinary metabolites and UACR
Values are expressed as mean ± SE; Keys: TMAO, trimethylamine oxide; GTP, guanosine triphosphate; **P < 0.01 compared with age-matched wildtype mice.

Table 2. Summary of the potential biomarkers in kidney extracts from db/db mice and wildtype mice. Values are expressed as mean ± SE; Keys: TMAO, trimethylamine oxide; GTP, guanosine triphosphate; **P < 0.01 compared with age-matched wildtype mice.

| δH(ppm) | metabolites            | metabolism pathway       | wildtype mice | db/db mice |
|---------|------------------------|--------------------------|---------------|------------|
| 1.342   | Lactate                | Glycolysis               | 38.78 ± 0.76  | 53.27 ± 2.42** |
| 1.919   | Acetate                | Fatty acids β-oxidation   | 3.31 ± 0.09   | 1.93 ± 0.09** |
| 1.206   | 3-hydroxybutyrate      | Ketogenesis               | 3.39 ± 0.20   | 1.52 ± 0.05** |
| 3.037   | Creatinine             | Serinolysis               | 7.59 ± 0.22   | 4.50 ± 0.28** |
| 3.204   | Choline                | Methylamine metabolism    | 21.12 ± 1.02  | 14.12 ± 0.87** |
| 4.275   | TMAO                   | Methylamine metabolism    | 7.52 ± 0.13   | 9.41 ± 0.28** |
| 3.625   | myo-Inositol           | Lipid metabolism          | 27.45 ± 0.26  | 28.47 ± 0.34 |
| 2.372   | Glutamate              | Amino acid metabolism     | 22.23 ± 0.42  | 12.68 ± 0.64** |
| 3.522   | Glycine                | Amino acid metabolism     | 16.05 ± 0.37  | 8.10 ± 0.52** |
| 6.909   | Tyrosine               | Amino acid metabolism     | 0.44 ± 0.01   | 0.39 ± 0.01** |
| 5.198   | Uracil                 | Pyrimidine metabolism     | 0.22 ± 0.01   | 0.16 ± 0.01** |
| 5.92    | Uridine                | Pyrimidine metabolism     | 0.88 ± 0.02   | 0.73 ± 0.04** |
| 5.94    | GTP                    | Purine metabolism         | 0.55 ± 0.01   | 0.47 ± 0.01** |

Glucose metabolism. Correlations among the different metabolites provide valuable information regarding their source metabolic pathways, whereas correlations between metabolite levels and UACR provide information regarding the relationship of the metabolites to the pathogenesis of DN. Together, these analyses could provide clues to the nature of enzymes and other proteins, potential drug targets, involved in the development and progression of DN.

Results of our analysis showed that there were increased concentrations of the TCA cycle intermediates such as citrate, 2-oxoglutarate, cis-aconitate, and fumarate in the majority of the urine samples of db/db mice. This might reflect either systemic stress caused by hyperglycemia or local effects on kidney tubular transport and impairment of mitochondrial function. Compared with 9-week-old mice, significantly higher levels of citrate and cis-aconitate were present in the db/db mice at later stages. This result suggests that TCA cycle is accelerated during the middle and late stages of DN. Notably, among the TCA cycle intermediates, only succinate level showed a decline. Therefore, it appears that pathways other than TCA cycle, such as specific succinate transporters, are responsible for the changes in succinate levels and may play a role in determining the disease status.

The elevated level of lactate found in the urine and renal tissue samples of db/db mice is indicative of increased glycolysis. These metabolic features of TCA cycle and increased glycolysis seen in db/db mice indicate that glucose metabolism is involved in the development of DN. Additionally, the significant correlations of cis-aconitate and fumarate with UACR, which were absent in the corresponding control mice, indicate that alterations in glucose metabolism contribute to the development and progression of DN.
Methylamine metabolism. Some methylamine metabolites are important non-perturbing renal osmolytes produced through the degradation of dietary choline to TMA and its di- and monoamine metabolites by the action of gut microflora. The decreased urinary concentrations of methylamine and DMA, and the renal concentration of choline in the db/db mice suggest the downregulation of methylamine pathway in DN. Their decline could be seen as due to osmotic compensation for elevated blood glucose concentrations or might indicate renal papillary dysfunction in DN. However, the renal concentration of TMAO showed a tendency different from that of other metabolites of the methylamine metabolism pathway. It is likely that other pathways contributed to the contradictions and further studies are needed to understand the precise nature of these contributing factors.

We found that DMA negatively correlated with UACR in the urine of db/db mice, which suggests that DMA plays a key role in the progression of DN. DMA circulates in the body and is excreted through urine. Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase,
is a major precursor of DMA\textsuperscript{23}. ADMA is hydrolyzed to DMA and L-citrulline by dimethylarginine dimethylaminohydrolase (DDAH). Therefore, pharmacological modulation of DDAH activity has been proposed as a method for manipulating endogenous DMA concentrations and regulating the production of nitric oxide (NO) in conditions where they have been shown to contribute to illnesses\textsuperscript{24}. It has been reported that DDAH plays an important role in childhood hypercholesterolemia\textsuperscript{25} and idiopathic pulmonary fibrosis\textsuperscript{26}. The anti-diabetic drug metformin has been shown to effectively modulate the metabolism of asymmetric dimethylarginine in experimental liver injury\textsuperscript{27}. The therapeutic action of relaxin during hypertension is also dependent on the modulation of endogenous DMA levels and DDAH activity\textsuperscript{28}. Thus, DDAH plays a key role in the maintenance of vascular homeostasis. Together with these earlier findings, our results suggest that inhibition of DDAH might be a promising therapeutic strategy for the treatment of patients suffering from DN.

**Fatty acid metabolism.** 3-HB and acetoacetate are products of ketone bodies and fatty acid metabolism in liver mitochondria\textsuperscript{29}. Our NMR analysis of the urine samples revealed decreased levels of 3-HB and acetoacetate in \( \text{db/db} \) mice throughout the course of the experiment, suggesting a reduced activity of ketogenesis pathway or the presence of mitochondrial dysfunction in DN. Additionally, we found that 3-HB positively correlated with acetoacetate in the urine of \( \text{db/db} \) mice, whereas such a correlation was absent in the control mice. These changes suggest significantly increased correlation between ketone bodies metabolism and the pathological state of DN. We also found that 3-HB and acetoacetate displayed significant negative correlations with UACR, indicating that these metabolites are associated with the pathogenesis of DN. In hepatic cells, 3-hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA lyase) functions as a rate-limiting enzyme that catalyzes the cleavage of HMG-CoA to acetoacetate, which is partly reduced to form 3-HB\textsuperscript{30}. Inhibition of HMG-CoA lyase activity by dietary polyphenols has been proposed as a therapeutic strategy for preventing ketoacidosis\textsuperscript{31}. Therefore, ketogenesis or HMG-CoA lyase or both may be potential targets for drugs in the treatment of DN.

Acetate is another important product of fatty acid \( \beta \)-oxidation and its decline in urine and kidney of \( \text{db/db} \) mice suggests significantly reduced fatty acid \( \beta \)-oxidation in DN. Together, these results are indicative of impaired fatty acid metabolism in \( \text{db/db} \) mice.

**Glycogenic amino acid metabolism.** Compared with that in the control mice, concentrations of glutamate, tyrosine, and glycine were lower in the kidney of \( \text{db/db} \) mice, suggesting that protein and
Amino acid metabolisms were impaired in diabetic mice. Both glycine and glutamate levels showed significant negative correlations with lactate in DN mice. Glycine and glutamate are important glycogenic amino acids. Thus, these negative correlations indicate enhancement of gluconeogenesis pathway during the pathogenesis of DN. Our analysis showed that glycine and glutamate positively correlated with UACR in the db/db mice, whereas such correlations were absent in the control mice. These results confirm that gluconeogenesis is closely related to the pathogenesis of DN. Ameliorating glucose metabolism by regulating gluconeogenesis is one of the important strategies against diabetic complications.

**Nucleotide metabolism.** 1-methylnicotinamide (MNA) is involved in the tryptophan-NAD\(^+\) pathway, which supplies pyridine nucleotides to the liver\(^5\). MNA has been suggested as urinary and plasma biomarkers of peroxisome proliferation in rats\(^9\). Because it affects oxidative and glycooxidative processes, MNA has been considered for potential applications in the prevention and treatment of various complications accompanying diabetes mellitus\(^34\). We found increased concentration of MNA in the urine of db/db mice, indicating the possible protective effects of the metabolite in DN. However, our results showed that there was no correlation between MNA and other important metabolites in the db/db mice. Therefore, MNA itself might not be regarded as a suitable therapeutic drug for DN.

The reduced levels of uracil, uridine, and GTP in the kidney of db/db mice suggest a disturbance in the nucleotide metabolism during the development of DN. The highly positive correlations of uridine and GTP levels with UACR indicate that nucleotide metabolism is closely related to the pathogenesis of DN. As a fundamental unit of all forms of life, GTP serves as a key donor substrate for protein and lipid phosphorylation\(^38\). Different pathological states are accompanied by changes in erythrocyte GTP concentrations. GTP cyclohydrolase I (GTPCH I) is the rate-limiting enzyme in the biosynthesis of BH4 from GTP, an essential cofactor for nitric oxide synthase and aromatic amino acid hydroxylase\(^36\). Mutation of GTPCH I has been identified as showing some therapeutic promises against cardiovascular or neurological diseases\(^37\). Therefore, pharmacological modulation of GTPCH I activity or GTP levels might be a promising new strategy for the treatment of DN.

**Changes in other metabolites.** Myo-inositol is a component of cell membranes and plays an important role in cell morphogenesis and cytogenesis, lipid synthesis, structure of cell membranes and cell growth\(^28\). The observed increase in the myo-inositol concentration in the kidney extracts of db/db mice indicates tubular dysfunction and renal cell stress under hyperglycemia, likely due to the downregulated expression of the myo-inositol oxygenase in db/db mice\(^39\). Myo-inositol has been suggested to play an important role in the etiology of diabetes mellitus, particularly with respect to the progression of DN, and its modulation has been shown to have a beneficial effect in restoring the impaired motor nerve conduction velocity and disruption of nerve structural elements\(^40\). However, our analysis showed no correlation of the metabolite with UACR. Further studies are needed to examine the possible role of myo-inositol in the development and progression of DN.

**Conclusions**

In summary, we integrated information obtained from the \(^1\)H NMR-based metabolomic analysis of urine and kidney samples of db/db and wildtype mice to characterize the systemic metabolic changes during the development of DN. Combined metabolic alterations and correlation analysis identified cis-aconitate and allantoin as potential biomarkers of DN. Also the results revealed that several enzymes, including DDAH, HMG-CoA lyase, and GTPCH I could be targeted for intervention. Together, the present results pave a way for elucidating the mechanisms underlying the development and progression of DN, provide new avenues for the diagnosis of DN and present potential targets for drug discovery.

**Methods**

**Animals.** BKS.Cg-m\(^+1\) Leprdb/J db/db (n = 10, male) mice that are deficient for leptin receptor (Lepr / Lepr\(^\text{−}\)) were used as DN models, while genetically normal C57BLKS/J wildtype mice (n = 15, male) were used as control\(^41\). The animals were obtained from Model Animal Research Center of Nanjing University, and kept in a SPF colony of the Laboratory Animal Center of Wenzhou Medical University with regulated temperature and humidity and a 12/12 h light–dark cycle for 10 weeks. During the entire experiment, mice were fed with standard chow and tap water. All animals received care in accordance to the ‘Guide for the Care and Use of Laboratory Animals.’ Procedures using mice were approved by the Institutional Animal Care and Use Committee of Wenzhou Medical College (document number: wydw2012-0083).

**Urine and kidney sample collection.** Urine samples were collected for 12 h after fasting at 9-, 11-, 13-, 15- and 17-weeks of age in metabolic cages individual. The urine samples were collected over ice into 0.1 ml of 1% sodium azide solution for avoiding bacterial contamination and then centrifuged for 10 min at 4°C. The supernatant was stored at −80°C until measurement. The body weight of the mice was measured weekly and the fasting blood glucose concentration was measured using a tail nick and glucometer (B/BRAUN omnitest plus). Animals were killed by cervical dislocation at the age of 17-weeks, and their renal tissues were dissected, immediately snap-frozen in liquid nitrogen, and stored at −80°C freezer until NMR experiments.
Clinical biochemistry and histological analysis. Clinical chemistry analysis of the urine was carried out on an automatic biochemistry analyzer (Mindray BS-300) using appropriate kits with the following parameters: CRE, UACR. The renal tissues were rapidly dissected, fixed overnight in 10% buffered formalin, and then embedded in paraffin, made into 4 mm sections and further stained with HE and PAS.

Preparation of samples and acquisition of 1H-NMR spectra. Before NMR analysis, urine samples were thawed, and 500 μL aliquots were mixed with 50 μL D2O containing TSP (0.36 mg/mL) and 300 μL of phosphate buffer (0.2 M Na2HPO4/NaH2PO4, pH 7.4) to minimize variations in pH. D2O provided a field-frequency lock, and TSP was used as the chemical shift reference. The mixtures were centrifuged to remove the precipitates, and then 500 μL of the supernatant was transferred to 5-mm NMR tubes. All NMR spectra were recorded at 25 °C on a Bruker AVANCE III 600 MHz NMR spectrometer equipped with a triple resonance probe and a z-axis pulsed field gradient. 1H NMR spectra were acquired using a one-dimensional NOESY pulse sequence with water suppression during the relaxation delay of 4 s and a mixing time of 150 ms. 128 free induction decays were collected into 32K data points with a spectral width of 12 000 Hz, an acquisition time of 2.66 s. FID was zero-filled to 64 K prior to Fourier transformation.

The frozen renal tissue was weighed and put into a centrifuge tube. Ice-cold methanol (4 mL/g) and distilled water (0.85 mL/g) was added into the tube, homogenized at 4 °C after thawing and mixed by vortex. Chloroform (2 mL/g) and distilled water (2 mL/g) was added into the tube and mixed again. After the sample tubes were kept on ice for 15 min, the homogenate was centrifuged at 1 000 g for 15 min at 4 °C. The supernatant was extracted and lyophilized for about 24 h. Before recording of the NMR spectra, the tissue extracts were resuspended in 500 μL D2O containing TSP (0.25 mM), and then after centrifugation the supernatant was transferred to 5 mm NMR tubes. 1H NMR spectra were acquired at 25 °C on a Bruker AVANCE III 600 MHz NMR spectrometer equipped with a triple resonance probe and a z-axis pulsed field gradient. A one-dimensional ZGPR pulse sequence was used to achieve satisfactory water suppression in aqueous extracts. For each sample, the relaxation delay was 6.0 s and the acquisition time was 2.66 s per scan. 128 transients were collected into 64 K data points with a spectral width of 12 000 Hz.

Data reduction and multivariate pattern recognition analysis. All NMR spectra were phased and baseline corrected, and then data-reduced to 1100 integrated regions of 0.01 ppm width corresponding to the region of δ 10 to −1 using the Topspin 2.1 software package for multivariate pattern recognition analysis. And another data-reduced to 7334 integrated regions of 0.0015 ppm width corresponding to the region of δ 10 to −1 for quantitative analysis. For NMR spectra recorded in kidney extracts, the region of about δ 4.69–5.04 was removed to eliminate artifacts related to the residual water resonance. The region of the urine spectra associated with residual water and urea (4.71–5.06 and 5.72–5.94 ppm) were removed. And due to the presence of conspicuous glucose metabolite, the resonances region of glucose of all spectra were also excluded.43 The remaining spectral segments were normalized to the total integral values were then input into the software of SPSS for Windows (Version 13.0, SPSS Inc., USA) for the statistical analysis. A two-tailed unpaired t-test was applied in order to detect significant differences in selected signals between two groups. A calculated P-value of less than 0.05 was considered statistically significant. Data were presented as mean ± SE.
References
1. Shao, N. et al. Relationship between Oxidant/Antioxidant Markers and Severity of Microalbuminuria in the Early Stage of Nephropathy in Type 2 Diabetic Patients. J. Diabetes Res. 2013, 232404 (2013).
2. Kanwar, Y. S., Sun, L., Xie, P., Liu, F. Y. & Chen, S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu. Rev. Pathol. 6, 395–423 (2011).
3. Shockcor, J. P. & Holmes, E. Metabonomic applications in toxicity screening and disease diagnosis. Curr. Top. Med. Chem. 2, 35–51 (2002).
4. Nicholson, J. K. Global systems biology, personalized medicine and molecular epidemiology. Mol. Syst. Biol. 2, 52 (2006).
5. Nicholson, J. K., Lindon, J. C. & Holmes, E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29, 1181–1189 (1999).
6. Psilogios, N. G., Gazi, I. F., Elisaf, M. S., Sefriadius, K. I. & Bairaktari, E. T. Gender-related and age-related urinary analysis of healthy subjects by NMR-based metabonomics. NMR Biomed. 21, 195–207 (2008).
7. Zhao, L., et al. 1H-NMR-based metabonomic analysis of metabolic profiling in diabetic nephropathy rats induced by streptozotocin. Am. J. Physiol. Renal Physiol. 300, F947–956 (2011).
8. Diao, C. et al. Systemic and characteristic metabolites in the serum of streptozotocin-induced diabetic rats at different stages as revealed by a 1H-NMR based metabonomic approach. Mol. Biostds. 10, 686–693 (2014).
9. Guan, M. et al. Systemic perturbations of key metabolites in diabetic rats during the evolution of diabetes studied by urine metabonomics. PLoS One 8, e60409 (2013).
10. Li, M. et al. GC/TOFMS analysis of metabolites in serum and urine reveals metabolic perturbation of TCA cycle in db/db mice involved in diabetic nephropathy. Am. J. Physiol. Renal Physiol. 304, F3137–3134 (2012).
11. Liu, J. et al. 1H NMR-based metabonomic analysis of serum and urine in a nonhuman primate model of diabetic nephropathy. Mol. Biostds. 9, 2645–2652 (2013).
12. Sharma, K., McCue, P. & Dunn, S. R. Diabetic kidney disease in the db/db mouse. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 233, 4–11 (2008).
13. Pan, H. et al. Identification of proteins interacting with GTP cyclohydrolase I. Biochem. Biophys. Res. Commun. 385, 143–147 (2009).
14. Pan, H. et al. A metabolomic comparison of diabetic kidney in the db/db mouse. Am. J. Physiol. Renal Physiol. 284, F1138–1144 (2003).
15. Huang, J. et al. Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus. BMC Med. Genomics 2, 41 (2009).
16. Akira, K., Masu, S., Imachi, M., Mitome, H. & Hashimoto, T. A metabonomic study of biochemical changes characteristic of genetically hypertensive rats based on 1H NMR spectroscopic urinary. Hypertens Res. 35, 404–412 (2012).
17. Teimoury, A., Iraj, B., Heidari-Beni, M., Amini, M. & Hosseiny, S. M. Why 24-h Urine Albumin Excretion Rate Method Still is Used for Screening of Diabetic Nephropathy in Isfahan Laboratories? Int. J. Prev. Med. 5, 341–347 (2014).
18. Boudaoud, K. J. et al. Discovery of biomarkers for early detection of nephotoxicity. Toxicol. Pathol. 37, 280–292 (2009).
19. Zupp, C. et al. Proton nuclear magnetic resonance spectral profiles of urine from children and adolescents with type 1 diabetes. Clin. Chem. 48, 660–662 (2002).
20. Briggs, J. P., Levi, M. F. & Abrams, R. G. Renal excretion of allantoin in rats: a micropuncture and clearance study. Am. J. Physiol. 233, F373–381 (1977).
21. Salek, R. M. et al. A metabonomic comparison of urinary changes in type 2 diabetes in mouse, rat, and human. Physiol. Genomics 29, 99–108 (2007).
22. Pettit-Peterdi, J. High glucose and renin release: the role of succinate and GPR91. Am. J. Physiol. Renal Physiol. 307, F1317–1324 (2014).
23. Chobanyan, K., Mitschke, A., Gutzk, F. M., Stichtenoth, D. O. & Tsikas, D. Accurate quantification of dimethylamine (DMA) in human plasma and serum by GC-MS and GC-tandem MS as pentalfluorobenzamide derivative in the positive-ion chemical ionization mode. J. Chromatogr. B. Analit. Technol. Biomed. Life Sci. 851, 240–249 (2007).
24. Brinkmann, S. J., de Boer, M. C., Buys, N. & van Leeuwen, P. A. Asymmetric dimethylarginine and critical illness. Curr. Opin. Clin. Nutr. Metab. Care 17, 90–97 (2014).
25. Choban-Engel, K. et al. Increased asymmetric dimethylarginine (ADMA) dimethylaminohydrolase (DDAH) activity in childhood hypercholesterolemia type II. Amino Acids 43, 805–811 (2012).
26. Pullamsetti, S. S. et al. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci. Transl. Med. 3, 8ra53 (2011).
27. Bal, F. et al. Antidiabetic drug metformin is effective on the metabolism of asymmetric dimethylarginine in experimental liver injury. Diabetes Res. Clin. Pract. 106, 295–302 (2014).
28. Sasser, J. M., Cunningham, M. W., Jr. & Baylis, C. Serelaxin reduces Oxidative Stress and Asymmetric Dimethylarginine in Angiotension II Induced Hypertension. Am. J. Physiol. Renal Physiol. 307, F1355–1362 (2014).
29. Wu, H. et al. NMR spectroscopic-based metabonomic investigation on the acute biochemical effects induced by Ce(NO3)3 in rats. J. Inorg. Biochem. 99, 2151–2160 (2005).
30. Fu, Z. Runquist, J. A., Montgomery, C., Miziolek, H. M. & Kim, J. J. Functional insights into human HMG-CoA lyase from structures of Acyl-CoA-containing ternary complexes. J. Biol. Chem. 285, 26341–26349 (2010).
31. Nakagawa, S., Kojima, Y., Sekino, K. & Yamato, S. Effect of polyphenols on 3-hydroxy-3-methylglutaryl-coenzyme A lyase activity in human hepatoma HepG2 cell extracts. Biol. Pharm. Bull. 36, 1902–1906 (2013).
32. Wolf, H. The effect of hormones and vitamin B6 on urinary excretion of metabolites of the kynurenine pathway. Scand. J. Clin. Lab. Invest. Suppl. 136, 1–186 (1974).
33. Connor, S. C. et al. Development of a multivariate statistical model to predict peroxisome proliferation in the rat, based on urinary 1H-NMR spectral patterns. Biomarkers 9, 364–385 (2004).
34. Orszaghoval, Z. et al. Effects of N1-methylcotianamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus. Redox Rep. 17, 1–7 (2012).
35. Dagher, P. C. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int. 66, 506–509 (2004).
36. Ren, J. Hope or hype: The obsession for tetrahydrobiopterin and GTP cyclohydrolase I (GTPCH I) in cardiovascular medicine. J. Cardiothorac. Renal Res. 1, 15–21 (2006).
37. Du, J. et al. Identification of proteins interacting with GTP cyclohydrolase I. Biochem. Biophys. Res. Commun. 385, 143–147 (2009).
38. Carlomagnu, G., De Grazia, S., Unfer, V. & Mannu, F. Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use. Expert Opin. Drug Deliv. 9, 267–271 (2012).
39. Kanwar, Y. S. et al. Diabetic nephropathy: mechanisms of renal disease progression. Exp. Biol. Med. (Maywood) 233, 4–11 (2008).
40. Prahlad, K. S., Arne, R. J., Vunta, H. & Reddy, C. C. Up-regulation of human myo-inositol oxygenase by hypoxemic stress in renal proximal tubular epithelial cells. J. Biol. Chem. 280, 19895–19901 (2005).
41. Ghosh, S. et al. Moderate exercise attenuates caspase-3 activity, oxidative stress, and inhibits progression of diabetic renal disease in db/db mice. *Am. J. Physiol. Renal Physiol.* **296**, F700–708 (2009).
42. Xiao, C., Hao, F., Qin, X., Wang, Y. & Tang, H. An optimized buffer system for NMR-based urinary metabonomics with effective pH control, chemical shift consistency and dilution minimization. *Analyst* **134**, 916–925 (2009).
43. Zhang, S. et al. Correlative and quantitative 1H NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. *Anal. Biochem.* **383**, 76–84 (2008).
44. Westerhuis, J. A., van Velzen, E. J., Hoefsloot, H. C. & Smilde, A. K. Multivariate paired data analysis: multilevel PLS-DA versus OPLS-DA. *Metabolomics* **6**, 119–128 (2010).
45. Weljie, A. M., Dowlatshahi, R., Miller, B. J., Vogel, H. J. & Jirik, F. R. An inflammatory arthritis-associated metabolite biomarker pattern revealed by 1H NMR spectroscopy. *J. Proteome Res.* **6**, 3456–3464 (2007).
46. Cloarec, O. et al. Evaluation of the orthogonal projection on latent structure model limitations caused by chemical shift variability and improved visualization of biomarker changes in 1H NMR spectroscopic metabolomic studies. *Anal. Chem.* **77**, 517–526 (2005).

**Acknowledgments**

This work was supported by the National Natural Science Foundation of China (Nos. 21175099, 81400863), Research Fund for the Doctoral Program of Higher Education of China (No. 2013321120006), Zhejiang Provincial Natural Science Foundation (Nos. LY13H070005, LY14H090014, LY15H180010), and Guangxi Provincial Project of higher School Sponsored Research (201003YB028).

**Author Contributions**

T.T.W. and L.C.Z. planned the study, carried out the laboratory experiments, analyzed data, and developed the manuscript. J.M.J., H.H.X., Y.D., Q.T.L. and X.D.L. performed the experiments, participated in discussion and reviewed and edited the manuscript. Z.H.Y. and X.J.Y. contributed to the data analysis and discussion, and reviewed the manuscript. H.C.G. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Wei, T. *et al.* Metabonomic analysis of potential biomarkers and drug targets involved in diabetic nephropathy mice. *Sci. Rep.* **5**, 11998; doi: 10.1038/srep11998 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/